Table 6.
Anti-gout study (knee diameter) of the Sprague–Dawley rats after their treatment with ALP-loaded NLCs gel and its comparison with ALP suspension and untreated rats groups.
| Treatment group | Day (s) | ||||
|---|---|---|---|---|---|
| 0 | 7 | 15 | 30 | 45 | |
| Knee diameter (mm) | |||||
| Gout induced untreated | |||||
| GR1 | 4.11 | 8.42 | 8.46 | 8.48 | 8.49 |
| GR2 | 3.92 | 7.90 | 7.91 | 7.93 | 7.92 |
| GR3 | 3.84 | 7.74 | 7.77 | 7.79 | 7.80 |
| GR4 | 4.45 | 8.75 | 8.76 | 8.78 | 8.77 |
| GR5 | 4.30 | 8.61 | 8.63 | 8.66 | 8.64 |
| GR6 | 4.12 | 9.53 | 9.52 | 9.55 | 9.56 |
| ALP suspension | |||||
| SR1 | 3.83 | 7.67 | 6.31 | 5.43 | 4.39 |
| SR2 | 4.22 | 8.23 | 6.94 | 6.01 | 4.89 |
| SR3 | 4.43 | 8.54 | 7.07 | 6.13 | 4.97 |
| SR4 | 4.56 | 8.47 | 7.19 | 6.26 | 4.85 |
| SR5 | 3.70 | 7.64 | 6.08 | 5.40 | 4.24 |
| SR6 | 3.85 | 7.79 | 6.21 | 5.33 | 4.48 |
| ALP-loaded NLCs gel | |||||
| NGR1 | 3.78 | 7.94 | 6.21 | 5.07 | 3.84 |
| NGR2 | 4.07 | 7.99 | 6.18 | 5.11 | 4.12 |
| NGR3 | 4.63 | 8.47 | 6.72 | 5.79 | 4.67 |
| NGR4 | 4.34 | 8.35 | 6.81 | 5.76 | 4.48 |
| NGR5 | 4.71 | 7.89 | 6.57 | 5.69 | 4.80 |
| NGR6 | 4.86 | 8.31 | 7.04 | 5.48 | 4.89 |